Back to Search
Start Over
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM)
- Source :
- Journal of Clinical Oncology. 32:2021-2021
- Publication Year :
- 2014
- Publisher :
- American Society of Clinical Oncology (ASCO), 2014.
-
Abstract
- 2021 Background: Patients (pts) with recurrent GBM have few treatment options and a very poor prognosis. GBM tumors often exhibit aberrant epidermal growth factor receptor (EGFR) proliferative sign...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Poor prognosis
Temozolomide
integumentary system
biology
urogenital system
business.industry
Treatment options
Pharmacology
urologic and male genital diseases
medicine.disease
female genital diseases and pregnancy complications
nervous system diseases
Internal medicine
medicine
biology.protein
Epidermal growth factor receptor
business
Glioblastoma
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........5fe534b791077c83308e4b8c3b494217